NCT02765490View on ClinicalTrials.gov

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

365

Participants

Timeline

Start Date

November 9, 2016

Primary Completion Date

August 9, 2017

Study Completion Date

November 16, 2017

Conditions

Hepatitis C, Chronic

Interventions

DRUG

AL-335

AL-335 800 mg (2\*400) tablet will be administered once daily.

DRUG

Odalasvir

Odalasvir 25 mg tablet will be administered once daily.

DRUG

Simeprevir

Simeprevir 75 mg capsule will be administered once daily.

Trial Locations (28)

Unknown

Antwerp

Brussels

Edegem

Ghent

Kortrijik

Leuven

Vancouver

Victoria

Toronto

Vaughan

Monteral

Montreal

Berlin

Essen

Frankfurt

Hamburg

Leipzig

Lodz

Lublin

Mysłowice

Warsaw

Wroclaw

Singapore

Barcelona

Madrid

Málaga

Seville

Valencia

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02765490 - Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection | Biotech Hunter | Biotech Hunter